Submitted by: Submitted by williamdonald
Views: 10
Words: 1163
Pages: 5
Category: Business and Industry
Date Submitted: 05/16/2016 12:54 AM
Summary
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.
T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.
Browse Detail Report With TOC @ http://www.hexareports.com/report/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets/details
Scope
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of...